Talk:Peroxisome proliferator-activated receptor gamma

	This article is within the scope of WikiProject Molecular Biology, a collaborative effort to improve the coverage of Molecular Biology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Molecular BiologyWikipedia:WikiProject Molecular BiologyTemplate:WikiProject Molecular BiologyMolecular Biology articles
???	This article has not yet received a rating on the importance scale.
	This article is supported by the Molecular and Cell Biology task force (assessed as Low-importance).

Neuroscience Low‑importance

	This article is within the scope of WikiProject Neuroscience, a collaborative effort to improve the coverage of Neuroscience on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.NeuroscienceWikipedia:WikiProject NeuroscienceTemplate:WikiProject Neuroscienceneuroscience articles
Low	This article has been rated as Low-importance on the project's importance scale.

Outdated reading

Moving this section here for discussion and/or archiving. All are primary research or opinions which appear to have been included in the article as initial insights. WP:SCIRS reviews should prevail.

Qi C, Zhu Y, Reddy JK (2001). "Peroxisome proliferator-activated receptors, coactivators, and downstream targets". Cell Biochemistry and Biophysics. 32 Spring (1–3): 187–204. doi:10.1385/cbb:32:1-3:187. PMID 11330046. S2CID 31795393.
Kadowaki T, Hara K, Kubota N, Tobe K, Terauchi Y, Yamauchi T, et al. (2002). "The role of PPARgamma in high-fat diet-induced obesity and insulin resistance". Journal of Diabetes and Its Complications. 16 (1): 41–5. doi:10.1016/S1056-8727(01)00206-9. PMID 11872365.
Wakino S, Law RE, Hsueh WA (2002). "Vascular protective effects by activation of nuclear receptor PPARgamma". Journal of Diabetes and Its Complications. 16 (1): 46–9. doi:10.1016/S1056-8727(01)00197-0. PMID 11872366.
Takano H, Komuro I (2002). "Roles of peroxisome proliferator-activated receptor gamma in cardiovascular disease". Journal of Diabetes and Its Complications. 16 (1): 108–14. doi:10.1016/S1056-8727(01)00203-3. PMID 11872377.
Stumvoll M, Häring H (August 2002). "The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism". Diabetes. 51 (8): 2341–7. doi:10.2337/diabetes.51.8.2341. PMID 12145143.
Koeffler HP (January 2003). "Peroxisome proliferator-activated receptor gamma and cancers". Clinical Cancer Research. 9 (1): 1–9. PMID 12538445.
Puigserver P, Spiegelman BM (February 2003). "Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator". Endocrine Reviews. 24 (1): 78–90. doi:10.1210/er.2002-0012. PMID 12588810.
Takano H, Hasegawa H, Nagai T, Komuro I (May 2003). "The role of PPARgamma-dependent pathway in the development of cardiac hypertrophy". Drugs of Today. 39 (5): 347–57. doi:10.1358/dot.2003.39.5.799458. PMID 12861348.
Rangwala SM, Lazar MA (June 2004). "Peroxisome proliferator-activated receptor gamma in diabetes and metabolism". Trends in Pharmacological Sciences. 25 (6): 331–6. doi:10.1016/j.tips.2004.03.012. PMID 15165749.
Cuzzocrea S (July 2004). "Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury". Vascular Pharmacology. 41 (6): 187–95. doi:10.1016/j.vph.2004.10.004. PMID 15653094.
Savage DB (January 2005). "PPAR gamma as a metabolic regulator: insights from genomics and pharmacology". Expert Reviews in Molecular Medicine. 7 (1): 1–16. doi:10.1017/S1462399405008793. PMID 15673477.
Pégorier JP (April 2005). "[PPAR receptors and insulin sensitivity: new agonists in development]". Annales d'Endocrinologie. 66 (2 Pt 2): 1S10–7. PMID 15959400.
Tsai YS, Maeda N (April 2005). "PPARgamma: a critical determinant of body fat distribution in humans and mice". Trends in Cardiovascular Medicine. 15 (3): 81–5. doi:10.1016/j.tcm.2005.04.002. PMID 16039966.
Gurnell M (December 2005). "Peroxisome proliferator-activated receptor gamma and the regulation of adipocyte function: lessons from human genetic studies". Best Practice & Research. Clinical Endocrinology & Metabolism. 19 (4): 501–23. doi:10.1016/j.beem.2005.10.001. PMID 16311214.
Cecil JE, Watt P, Palmer CN, Hetherington M (June 2006). "Energy balance and food intake: the role of PPARgamma gene polymorphisms". Physiology & Behavior. 88 (3): 227–33. doi:10.1016/j.physbeh.2006.05.028. PMID 16777151. S2CID 54243343.
Rousseaux C, Desreumaux P (2007). "[The peroxisome-proliferator-activated gamma receptor and chronic inflammatory bowel disease (PPARgamma and IBD)]". Journal de la Société de Biologie. 200 (2): 121–31. doi:10.1051/jbio:2006015. PMID 17151549.
Eriksson JG (April 2007). "Gene polymorphisms, size at birth, and the development of hypertension and type 2 diabetes". The Journal of Nutrition. 137 (4): 1063–5. doi:10.1093/jn/137.4.1063. PMID 17374678.
Tönjes A, Stumvoll M (July 2007). "The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma in diabetes risk". Current Opinion in Clinical Nutrition and Metabolic Care. 10 (4): 410–4. doi:10.1097/MCO.0b013e3281e389d9. PMID 17563457. S2CID 30323803.
Burgermeister E, Seger R (July 2007). "MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma". Cell Cycle. 6 (13): 1539–48. doi:10.4161/cc.6.13.4453. PMID 17611413.
Papageorgiou E, Pitulis N, Msaouel P, Lembessis P, Koutsilieris M (August 2007). "The non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell lines". Expert Opinion on Therapeutic Targets. 11 (8): 1071–85. doi:10.1517/14728222.11.8.1071. PMID 17665979. S2CID 86480850.

Zefr (talk) 15:53, 17 October 2022 (UTC)[reply]

Outdated reading

Further reading